More consistent TIL assessments, more accurate patients' prognoses: New research shows how AI sharpens pathologists' interpretation of tissue samples for malignant melanoma.
Newly developed technology can detect breast cancer relapses up to five years in advance. This advance could represent a turning point in post-treatment follow-up, the researchers hope.
New research shows that dysfunction in the mitochondria linked to amyotrophic lateral sclerosis (ALS) occurs before the cells show other signs of disease, which was not previously known.
Dutch researchers have developed an AI tool to support Mohs surgery, a precise but time-consuming procedure to treat the most common form of cancer in the Netherlands: basal cell carcinoma.
Due to the effects of climate change, dengue is spreading worldwide. Now, researchers have developed a 'dengue-on-a-chip' model that helps study the virus more effectively.
A new method to quickly and accurately analyze the structure of collagen in tissue shows promise to improve the diagnostics of cancer and other diseases.
The evolving role of AI tools in digital pathology was explored at an open discussion during the annual Digital Pathology and AI Congress in London with a high-level panel of practitioners looking at current and future technology options. The panel of pathologists, scientists and academics from Europe and the USA assessed the tools they currently use and are available to them, and those they…
The location and timing of breast cancer recurrence may allow AI to predict the risk of metastasis, a new study shows. This is an essential step towards developing personalised treatment strategies.
In today’s fast-paced healthcare landscape, efficiency and accuracy are essential in overcoming workload challenges. Pathology laboratories are under pressure to keep up with growing demands, all while ensuring standardised, consistent and high-quality results.
New research reveals that self-generated electrical activity of small cell lung cancer (SCLC) directly promotes tumor metastasis and progression. This may provide new avenues for future treatments.
For patients, a liquid biopsy which checks for circulating tumour DNA of colon cancer, resembles a standard blood test. However, the method helps avoid chemotherapy for many, a new study finds.
There is no known cure for Alzheimer’s disease (AD), although prescription drug-based treatments that can slow AD progression in some patients are starting to enter clinical use. Biomarkers, quantifiable characteristics of biological processes or pathological conditions of the body, are making it possible to help identify and measure the presence and extent of AD and its degenerative…
Blood-based biomarker (BBB) tests may represent the best weapon to combat the soaring rates of Alzheimer’s disease (AD) throughout the world. Existing clinically validated tests are currently deployed to facilitate diagnosis, to monitor disease and effectiveness of treatments, to quantify progression, and to determine if a patient is appropriate for treatment or participation in a clinical…
Researchers developed an advanced AI tool for automatic analysis of colorectal cancer tissue slides. The new model outperformed all predecessors in the classification of tissue microscopy samples.
New research highlights the potential of circulating tumor DNA (ctDNA) analysis as a non-invasive method to identify actionable biomarkers for breast cancer, enabling individualized therapies.
Traumatic brain injury (TBI) increases dementia risk, but the reasons are poorly understood. Now, a study explores the role of the brain's blood vessels as drivers of Alzheimer's disease.
Helping the brain repair itself after a stroke: A new study based on unique tissue samples from Denmark's Brain Bank may pave the way for new treatments that support brain regeneration.
Liverpool physicists have developed a “diagnostic infrared wand” to more accurately predict the prognosis of oral cancer lesions than current H&E staining techniques.
Complex diseases could require complex biomarkers for accurate diagnosis in the years ahead, according to a leading pathologist. In a keynote address to the 36th European Congress of Pathology in Florence, Italy, Professor Manuel Salto-Tellez highlighted this as one of the major future challenges for the discipline. However, he also believes pathologists will sit at the core of modern medicine.
